' fill='%23ffffff'%3E%3Cpath d='M283.94,167.31l386.39,516.64L281.5,1104h87.51l340.42-367.76L984.48,1104h297.8L874.15,558.3l361.92-390.99 h-87.51l-313.51,338.7l-253.31-338.7H283.94z M412.63,231.77h136.81l604.13,807.76h-136.81L412.63,231.77z'%3E%3C/path%3E%3C/g%3E%3C/svg%3E%0A){kind=small}
Stateside research mission focuses on dementia and neuroprogressive disease
26th February 2018
Dementia and neuroprogressive conditions will be the focus of discussions in the USA this week as representatives from NHS Research Scotland travel to Boston.
Supported by Scottish Development International, the NHS Research Scotland delegation will meet with research and development leads from leading pharmaceutical companies to match expertise and capability in Scotland with current drug pipelines. It builds upon Scotland’s ambition to increase the level of high-quality health research conducted in Scotland for the health and financial benefits of our population.
Scotland’s research strengths are well established, and together our world-leading NHS, internationally renowned universities and industry form an interconnected network of experts and facilities that support research involving all life science sectors. This mission will focus specifically on dementia and neuroprogressive conditions.
“This is an excellent opportunity to further establish Scotland’s reputation as a leading research destination with partners in the US. As a major hub of America’s Life Science sector, Boston is an important market for us and we look forward to developing valuable relationships that will help attract further studies to Scotland”
Dr Steven Burke, Industry Liaison Manager, NHS Research Scotland
“Dementia is one of the foremost public health challenges worldwide. At the same time, neuroprogressive diseases including Motor Neurone Disease, Parkinson’s Disease, Huntington’s Disease, and Multiple Sclerosis are increasingly understood to have commonality in underlying causes, patient experience, symptoms and their management. Scotland has the expertise, infrastructure and energy to attract ambitious research projects into these debilitating diseases. With a successful record of industry collaboration and a proud history of driving advances in medicine, Scotland can and must lead the way in driving more research to answer the big questions around complex neurological conditions and deliver better treatments. I look forward to discussing possible collaborations over the coming days”
Dr Peter Connelly, Research Champion, NRS Neuroprogressive and Dementia Network
“Our network is committed to advancing understanding of dementia and neuroprogressive disease. These are devastating conditions and research is crucial to support development of new treatments. This mission supports our ambitions to attract and deliver more research in Scotland ultimately leading to improved treatment options and better outcomes for patients”
Emma Law, Network Manager, NRS Neuroprogressive and Dementia Network
The NRS Neuroprogressive and Dementia Network (NRS NDN) is funded by the Chief Scientist Office (CSO) to promote a culture of clinical research in dementia and neuroprogressive disease across Scotland. It is committed to working in partnership to build and expand research capacity in Scotland.
Notes
- Working closely with industry is a key priority for NHS Research Scotland. View our case studies
- First Minister Nicola Sturgeon outlines Scotland's research strengths and ethos of collaboration
- Read more Find out more about NRS Neuroprogressive and Dementia by visiting www.nrs.org.uk/dementia
- Read more about the work of NRS NDN by downloading case studies on industry and patient involvement
- The inaugural Neuroprogressive Conditions Research Day will be held on Thursday 19 April at the West Park Centre, Dundee, hosted by the Chief Scientist Office of the Scottish Government and NRS NDN - find out more on the NRS news feed
